3b型CHC的流行、诊断和治疗现状概述

摘要/Abstract

摘要： 全球丙型肝炎患者众多,据统计,2015年全球约有7 100万慢性丙型肝炎(chronic hepatitis C,CHC)患者。其中基因3b型CHC与肝脏疾病进展关系密切,且突变率高,治疗具有挑战性。由于CHC的临床表现缺乏特异性,现有检查方法存在局限性,其诊断存在相对困难。直接作用抗病毒药物的出现极大提高了丙型肝炎患者的持续病毒学应答率(sustained virological response, SVR),但其治疗3b型CHC的疗效及影响因素的相关资料仍不充分。本文就3b型慢性丙型肝炎的流行情况及诊治现状进行讨论。

关键词: 慢性丙型肝炎, 诊断, 治疗, 3b型

徐艳雯, 王鑫, 梁晨晨, 刘立, 李生浩, 高建鹏, 姜华. 3b型CHC的流行、诊断和治疗现状概述[J]. 肝脏, 2022, 27(12): 1351-1355.

参考文献

[1] 崔富强,庄辉. 中国建国以来防控病毒性肝炎工作进展. 中华肝脏病杂志,2021,29:725-731.
[2] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 实用肝脏病杂志,2020,23:33-52.
[3] 王晓忠,魏来. 中国慢性丙型肝炎基因3型患者的现状、治疗和展望. 中华肝脏病杂志,2020,28:824-826.
[4] Welzel TM, Bhardwaj N, Hedskog C, et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol, 2017,67:224-236.
[5] Chen Y, Yu C, Yin X, et al. Hepatitis C virus genotypes and subtypes circulating in mainland China. Emerg Microbes Infect, 2017,6:e95.
[6] 白娜. 血清HCV-RNA载量及抗-HCV浓度检测在丙型肝炎临床诊断中的应用分析. 临床血液学杂志,2018,31:922-924.
[7] 国家卫生和计划生育委员会. WS 213—2018丙型肝炎诊断. 临床肝胆病杂志,2018,34:1619-1621.
[8] 朱海超,甘建和. 南阳地区丙型病毒性肝炎患者病历资料分析. 中国艾滋病性病,2019,25:285-288.
[9] Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am, 2015,44:717-734.
[10] Hissar SS, Goyal A, Kumar M, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol, 2006,78:452-458.
[11] 冯小飞,丁国伟,俞海亮,等. 医疗机构丙型肝炎诊断治疗现况研究. 中国艾滋病性病,2020,26:247-249.
[12] 赵会霞,孙书芳,王同显. 隐匿性丙型肝炎病毒流行病学特点与输血安全. 中国输血杂志,2021,34:793-796.
[13] Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol, 1993,74:2391-2399.
[14] Yang R, Cong X, Du S, et al. Performance comparison of the versant HCV genotype 2.0 assay (LiPA) and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6. J Clin Microbiol, 2014,52:3685-3692.
[15] Asselah T, Bièche I, Mansouri A, et al. In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol, 2010,221:264-274.
[16] Baiocchini A, Montaldo C, Conigliaro A, et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution. PLoS One, 2016,11:e0151736.
[17] Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol, 2007,9:1089-1097.
[18] Wei L, Omata M, Lim YS, et al. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in mainland China. Antiviral Res, 2018,158:178-184.
[19] Lu J, Feng Y, Chen L, et al. Subtype-specific prevalence of hepatitis c virus ns5a resistance associated substitutions in mainland China. Front Microbiol, 2019,10:535.
[20] Schvarcz R, Ando Y, Sönnerborg A, et al. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol, 1995,23:17-21.
[21] McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther, 2019,17:775-785.
[22] Wei L, Lim SG, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol, 2019,4:127-134.
[23] Hu C, Yuan G, Liu J, et al. Sofosbuvir-based therapies for patients with hepatitis c virus infection: real-world experience in China. Can J Gastroenterol Hepatol, 2018,2018:3908767.
[24] Mei YY, Chen YM, Wu YK, et al. Efficacy and safety of sofosbuvir-based direct-acting antiviral agents treatment for patients with genotype 3/6 hepatitis C virus infection. Can J Gastroenterol Hepatol, 2020,2020:8872120.
[25] Mehta V, Mahajan R, Midha V, et al. Impact of direct acting antiviral therapy for treatment of hepatitis C genotypes 1, 3 and 4: a real life experience from India. J Clin Exp Hepatol, 2018,8:7-14.
[26] Ji F, Li J, Liu L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. J Gastroenterol Hepatol, 2021,36:767-774.
[27] Wei L, Wang G, Alami NN, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol, 2020,5:839-849.
[28] Gao Y, Kong F, Li G, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. Liver Int, 2020,40:2685-2693.
[29] Wei L, Xie Q, Hou JL, et al. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. J Gastroenterol Hepatol, 2018,33:1168-1176.
[30] Huang R, Rao H, Xie Q, et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol, 2019,91:1313-1318.